140 related articles for article (PubMed ID: 6355949)
21. [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia].
Haruyama H; Shimazaki C; Nakanishi S; Hamami T; Nisio A; Isemura T; Katsume H; Nakagawa M; Ijichi H
Gan To Kagaku Ryoho; 1982 Mar; 9(3):516-21. PubMed ID: 6964037
[TBL] [Abstract][Full Text] [Related]
22. Possible differentiation of human acute myeloblastic leukemia cells by daily and intermittent administration of aclacinomycin-A.
Sakurai M; Sampi K; Hozumi M
Leuk Res; 1983; 7(2):139-43. PubMed ID: 6574295
[TBL] [Abstract][Full Text] [Related]
23. [Remission induction by ACM-A and BH-AC on acute promyelocytic leukemia which is resistant to DNR and CA (author's transl)].
Shimazaki C; Nakajima Y; Ura Y; Hamami T; Haruyama H; Isemura T; Nakagawa M; Ijichi H
Rinsho Ketsueki; 1981 Jul; 22(7):1116-22. PubMed ID: 6948970
[No Abstract] [Full Text] [Related]
24. Phase I-II trial of aclacinomycin A given in a four-consecutive-day schedule to patients with solid tumours. A South-East European Oncology Group (SEEOG) Study.
Kerpel-Fronius S; Gyergyay F; Hindy I; Decker A; Sawinsky I; Fäller K; Mechl Z; Nekulova M; Kolaric K; Tomek R
Oncology; 1987; 44(3):159-63. PubMed ID: 3474571
[TBL] [Abstract][Full Text] [Related]
25. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
Sampi K; Ogawa M; Kimura I; Ohnoshi T; Yamada K; Masaoka T; Wakui A; Meguro S; Nagai K; Kitani T
Gan To Kagaku Ryoho; 1986 Oct; 13(10):3021-7. PubMed ID: 3464230
[TBL] [Abstract][Full Text] [Related]
26. Idarubicin in refractory acute leukemia.
Fülle HH; Hellriegel KP
Onkologie; 1986 Jun; 9(3):152-3. PubMed ID: 3528962
[TBL] [Abstract][Full Text] [Related]
27. [Various induction therapies in older patients with acute myeloid leukemias].
Lutz D
Wien Klin Wochenschr; 1985 Feb; 97(3):137-40. PubMed ID: 3856968
[TBL] [Abstract][Full Text] [Related]
28. [Studies on hematological diseases in elderly patients. Part 4: Chemotherapeutic effect of aclarubicin (ACR) on acute nonlymphocytic leukemia in the aged].
Yorimitsu S; Takahashi I; Lai M; Ohmoto E; Aoyama S; Inagaki T; Ueda I; Nishimura M; Nakada H; Nonaka K
Nihon Ronen Igakkai Zasshi; 1986 May; 23(3):302-8. PubMed ID: 3463814
[No Abstract] [Full Text] [Related]
29. Aclacinomycin A: clinical development of a novel anthracycline antibiotic in the haematological cancers.
Warrell RP
Drugs Exp Clin Res; 1986; 12(1-3):275-82. PubMed ID: 3525076
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of acute myelogenous leukemia with concurrent administration of N4-behenoyl-ara-C, aclacinomycin A, 6-mercaptopurine and prednisolone].
Ino T; Saito M; Matsui T; Shimizu S; Shigemura H; Nakamura K; Ono Y; Okamoto M; Takada T; Imura H
Rinsho Ketsueki; 1985 Feb; 26(2):139-46. PubMed ID: 3860668
[No Abstract] [Full Text] [Related]
31. Successful treatment of acute megakaryoblastic leukaemia.
Ninomiya H; Nakazawa M; Shibuya A; Aoki Y; Nagasawa T; Abe T
Scand J Haematol; 1986 Feb; 36(2):147-53. PubMed ID: 3458290
[TBL] [Abstract][Full Text] [Related]
32. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of refractory acute lymphocytic leukemia in childhood with BH-AC, ACM, 6-MP, and prednisolone].
Karube T; Maehara M; Ijima H; Muchi H
Rinsho Ketsueki; 1984 May; 25(5):613-8. PubMed ID: 6590894
[No Abstract] [Full Text] [Related]
34. [Results obtained with the clinical use of adriamycin].
Esposito S; Taylor LA
Haematologica; 1971; 56(9):343-66. PubMed ID: 5004536
[No Abstract] [Full Text] [Related]
35. [Intravesical instillation therapy of aclacinomycin-A (ACM) for superficial bladder tumor].
Noguchi S; Kubota Y; Shuin T; Miura T; Moriyama M; Sakuramoto T; Oshima H
Hinyokika Kiyo; 1984 Sep; 30(9):1153-8. PubMed ID: 6596878
[TBL] [Abstract][Full Text] [Related]
36. [Differentiation of human promyelocytic leukemic cells (HL-60) induced by aclacinomycin-B].
Lu Y; Han J; Liu HY; Zhong GP; Yang S; Jia TZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1986 Jun; 8(3):211-3. PubMed ID: 2946461
[No Abstract] [Full Text] [Related]
37. [A case of acute promyelocytic leukemia complicated with severe esophageal stenosis caused by aclacinomycin A].
Kataoka T; Takeyama H; Watanabe E; Yano K
Gan To Kagaku Ryoho; 1985 Aug; 12(8):1686-9. PubMed ID: 3861136
[TBL] [Abstract][Full Text] [Related]
38. Age adapted induction and intensified consolidation therapy in acute myelogenous leukemia.
Kurrle E; Ehninger G; Freund M; Heil G; Hoelzer D; Link H; Mitrou PS
Onkologie; 1986 Jun; 9(3):141-3. PubMed ID: 3528959
[TBL] [Abstract][Full Text] [Related]
39. Aggressive combination chemotherapy of bone marrow relapse in childhood acute lymphoblastic leukemia containing aclacinomycin-A: a multicentric trial.
Fengler R; Buchmann S; Riehm H; Berthold F; Dopfer R; Graf N; Holldack J; Jobke A; Jürgens H; Klingebiel T
Haematol Blood Transfus; 1987; 30():493-6. PubMed ID: 3305216
[TBL] [Abstract][Full Text] [Related]
40. Aclacinomycin, cytosine arabinoside and thioguanine in relapsed or resistant acute myeloid leukemia.
Neri A; Comis M; Brugiatelli M; Martino B; Ronco F
Haematologica; 1989; 74(1):113-4. PubMed ID: 2498174
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
